ABSTRACT
AI governance is like one of those mythical creatures that everyone speaks of but which no one has seen. Sometimes, it is reduced to a list of shared principles such as transparency, non-discrimination, and sustainability; at other times, it is conflated with specific mechanisms for certification of algorithmic solutions or ways to protect the privacy of personal data. We suggest a conceptual and normative approach to AI governance in the context of a global digital public goods ecosystem to enable progress on the UN Sustainable Development Goals (SDGs). Conceptually, we propose rooting this approach in the human capability concept-what people are able to do and to be, and in a layered governance framework connecting the local to the global. Normatively, we suggest the following six irreducibles: a. human rights first; b. multi-stakeholder smart regulation; c. privacy and protection of personal data; d. a holistic approach to data use captured by the 3Ms-misuse of data, missed use of data and missing data; e. global collaboration ('digital cooperation'); f. basing governance more in practice, in particular, thinking separately and together about data and algorithms. Throughout the article, we use examples from the health domain particularly in the current context of the Covid-19 pandemic. We conclude by arguing that taking a distributed but coordinated global digital commons approach to the governance of AI is the best guarantee of citizen-centered and societally beneficial use of digital technologies for the SDGs.
ABSTRACT
Immunoglobulin G4-related disease (IgG4-RD) is a chronic multisystem immune-mediated disease. Histologically, it presents as infiltration with IgG4-secreting plasma cells affecting many organs such as the pancreas, lacrimal glands, salivary glands, kidneys, and arteries, resulting in chronic fibrosis and scarring within the tissue which over time forms into a mass. It is a slow-growing process that usually remains indolent until it causes a mass effect or tissue infiltration. Our patient was found to have a pancreatic mass on imaging concerning pancreatic neoplastic lesions. He subsequently underwent biopsy for histology/pathology and IgG4 levels, which led to our diagnosis of IgG4-RD. Imaging, blood tests, and, most importantly, histopathological features of the involved organ are important in determining the diagnosis. This is important as a treatment plan will be based on the given diagnosis, and patients with IgG4-RD respond very well to systemic steroid therapy.
ABSTRACT
Kaposi sarcoma (KS) is the most commonly diagnosed malignancy in HIV-infected patients. With new treatments, incidence and severity of KS have significantly decreased. A 57-year-old African American male with medical history of AIDS presented with progressively worsening cough, shortness of breath, fever, night sweats, and 60 lb weight loss. On physical examination, he had diffused dark purple skin lesions and decreased air entry in the right lower lung fields. Chest x-ray and subsequent chest computed tomography (CT) showed moderate right lung pleural effusion with scattered bilateral diffuse infiltrates. The patient's absolute CD4 count was 27 cells/microliter. Thoracentesis was negative for infection or malignancy. He was started on chemotherapy paclitaxel along with HAART for extensive pulmonary KS. Since starting the treatment, his condition has significantly improved with near complete resolution of the pleural effusion, oral, and skin lesions. In conclusion, the diagnosis of AIDS-related pulmonary KS is often clinical, typically based on the presence of mucocutaneous disease and compatible features on CT chest. The differential diagnosis of pulmonary KS is broad. A detailed evaluation should exclude an infectious etiology or other tumors. Chemotherapy along with HAART can be used for treatment of severe pulmonary KS.
